Pluripotent stem cell-based cardiac regenerative therapy for heart failure

Area of Science:

• Regenerative Medicine
• Cardiovascular Biology
• Stem Cell Therapy

Background:

• Severe heart failure necessitates alternatives to heart transplantation.
• Human pluripotent stem cells (hPSCs) can be differentiated into cardiomyocytes (hPSC-CMs).
• Eliminating undifferentiated hPSCs is crucial to prevent teratoma formation post-transplantation.

Purpose of the Study:

• To evaluate the potential of hPSC-CMs as an alternative to heart transplantation.
• To review current strategies and challenges in hPSC-CM transplantation for cardiac repair.
• To highlight ongoing research addressing safety and efficacy for clinical application.

Main Methods:

• Production of large numbers of hPSC-CMs with elimination of undifferentiated cells.
• Two primary transplantation strategies: intramyocardial injection and epicardial implantation of patches/engineered tissues.
• Investigation of less invasive methods, including catheter-based injections.
• Development of techniques to improve engraftment rates, such as co-transplantation with extracellular matrix or non-cardiomyocytes.

Main Results:

• Transplantation of hPSC-CMs into a myocardial infarction model in large animals improved cardiac function.
• Engrafted hPSC-CMs demonstrated maturation and vascularization by host microvessels.
• Less invasive delivery methods are under investigation.
• Strategies to enhance cell engraftment are being developed.

Conclusions:

• hPSC-CMs show significant potential for cardiac regenerative therapy.
• Further research is needed to address post-transplant arrhythmias, imaging, and immune rejection.
• Clinical application is in its early stages, with widespread adoption contingent on proven safety and efficacy.